Moderna, bird flu

As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even probable.
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine
TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.
Moderna gets $590M from US government for bird flu vaccine
Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats. Others, including GSK and Pfizer, are also at work on similar shots.
Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
The latest funding is a sign of how seriously the Biden administration appears to be taking the pandemic threat.
Moderna awarded $590M to help accelerate development of mRNA-based bird flu vaccine: HHS
Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an mRNA-based bird flu vaccine, health officials said.
Bird Flu: US Invests $590 Million to Fast-Track Vaccine Development
The Department of Health and Human Services has granted millions of dollars to Moderna to speed up bird flu vaccine development.
HHS gives Moderna $590M to 'accelerate' bird flu vaccine trials
The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains with pandemic potential.
Moderna Awarded $590 Million for Bird Flu Vaccine Development
The Department of Health and Human Services (HHS) will award roughly $590 million to Moderna to accelerate the development of mRNA-based pandemic influenza vaccines, including vaccines for avian flu strains, to ensure the United States is better prepared for future potential pandemics, according to a recent HHS news release.
Bird Flu Update: First Commercial Case In Georgia, Moderna Receives $590 Million To Develop Vaccine
According to the latest data from the Centers for Disease Control, the current bird flu outbreak has caused 67 human cases of bird flu in the U.S. and one death associated with the virus.
Underperforming Moderna Stock Boosted by Bird Flu Vaccine
Moderna Inc (NASDAQ:MRNA) stock is surging today, up 8.7% at $37.02 at last glance, after the vaccine maker was awarded $590 million from the U.S. Health and Human Services Department to speed up the development of its bird flu vaccine, as the virus spreads rapidly throughout the country.
Moderna Stock Jumps as Biotech Gets $590M From US To Develop Bird-Flu Vaccine
Key Takeaways Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023.
CDC upgrades its advisory on bird flu. Will Moderna’s stock get a boost?
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...
US awards Moderna $590 million for bird flu vaccine development
The U.S. government has awarded Moderna $590 million to advance the development of its bird flu vaccine, as the country ...